Corcept reports annual meeting outcomes

Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company with a market capitalization of $7.49 billion, announced the results of its 2025 annual meeting of stockholders held on June 10, 2025. The company, headquartered in Redwood (NYSE:RWT) City, California, has demonstrated remarkable performance with a 141.84% return over the past year. According to InvestingPro analysis, the company currently trades near its Fair Value. The company disclosed in a recent SEC filing the voting outcomes on several key proposals.

During the annual meeting, stockholders voted on three primary items. The first item was the election of nine directors to serve until the 2026 annual meeting. All nominated directors were elected with a significant majority of the votes cast. The second proposal was to ratify Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, which was approved. Lastly, the compensation of Corcept’s named executive officers was approved on an advisory basis.

The total number of shares entitled to vote was 106,044,683, with 92,327,139 shares represented at the meeting. The detailed voting results for each director as well as the other proposals were provided in the filing. The appointed directors, the ratification of the accounting firm, and the executive compensation plan received a clear affirmative from the majority of votes.

This filing with the SEC ensures transparency and provides shareholders with insights into corporate governance and executive compensation within Corcept Therapeutics. The company continues to comply with SEC regulations by disclosing the outcomes of shareholder votes and other material corporate events. Investors looking for deeper insights can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s financial health, valuation metrics, and growth prospects. The next earnings announcement is scheduled for July 30, 2025.

The information for this article is based on a press release statement.

In other recent news, Corcept Therapeutics has reported significant developments related to its Phase 3 ROSELLA trial, which evaluated the efficacy of relacorilant combined with nab-paclitaxel for treating platinum-resistant ovarian cancer. The trial successfully met its primary endpoint, showing a 30% reduction in the risk of disease progression for patients receiving the combination therapy compared to those on monotherapy. The median progression-free survival was extended to 6.5 months from 5.5 months, with an interim analysis also indicating an improvement in overall survival to 16.0 months from 11.5 months. These results, presented at the ASCO 2025 Annual Meeting and published in The Lancet, have prompted Corcept to expedite regulatory applications in the U.S. and Europe.

Additionally, Corcept’s first-quarter financial results revealed earnings per share of $0.17, surpassing analyst expectations of $0.14, although revenue fell short at $157.2 million against the anticipated $177.9 million. Despite the revenue miss, the company maintains its 2025 sales guidance for Korlym, projecting sales between $900 million and $950 million. Analyst firms have reacted to these developments, with H.C. Wainwright maintaining a Buy rating but adjusting its price target to $145, while Piper Sandler reaffirmed its Overweight rating with a $131 target. Both firms highlighted the potential of relacorilant as a future growth driver, with a New Drug Application already filed with the FDA.

Corcept’s management attributes the revenue shortfall to capacity issues with a pharmacy vendor, which have since been addressed, and remains optimistic about future growth. The company has noted a significant increase in Korlym prescriptions, indicating market expansion. Analysts from Piper Sandler foresee transformative growth opportunities for Corcept, driven by its developments in hypercortisolism treatments and the potential impact of relacorilant in oncology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.